Integrated DNA Technologies’ Post

Automating library preparation is easy with the right solution. Whether that's as part of an end-to-end NGS workflow or as an independent workcell, open, integrated automation solutions can unlock untapped potential. Enter LINQ... Our automation platform offers scalable, flexible solutions that reduces manual touchpoints and maximises resources 👏 Discover the impact automation could have on your omics lab by following the link below ⬇️ #Genomics #LabAutomation #NGS

Would you like to save time and money on your NGS sequencing experiments? Let’s schedule a few minutes to discuss our dedicated NGS solutions for target enrichment, library preparation and single cell that are easy to use and automate. #rnaseq #dnasequencing #genomics #transcriptomics #qiagen

Unlocking BioCompute Objects: Velsera's Commitment to Interoperability and Regulatory Excellence. At Velsera, we're shaping the future of bioinformatics and regulatory excellence. Collaborating with the BioCompute Object (BCO) community, we've pioneered the BCO standard to communicate complex Next Generation Sequencing (NGS) workflows for regulatory review. Our award-winning app simplifies the process of generating BCOs and won first prize in the precisionFDA BioCompute Object App-a-thon. The challenge? Demonstrating BCOs' interoperability. The introduction of Neoantigen Workflows is a prime example of our leadership on this journey. Our BCO app effortlessly generates a BCO from this sophisticated workflow, highlighting regulatory submission best practices. We're proud to partner with the Biocompute Object Working Group to set a standard for excellence, showing BCOs can seamlessly operate within the FDA. The Velsera team is excited to participate in the FDA Computing Days, Sept. 12-13, 2023! Our BCO working group, proudly sponsored by the FDA, is part of the innovation competition. Embrace innovation, interoperability, and regulatory excellence with Velsera. Interested in our BCO work? Reach out to our team today! https://lnkd.in/gdkw4vDa  #EraofVelsera #BCOInteroperability #Bioinformatics #RegulatoryExcellence #PrecisionFDA #NeoantigenWorkflow https://lnkd.in/gbGXj6YU

#Research can often feel like one step forward and ten steps back. Trial and error. Re-try, re-do, repeat. We get it. And that’s why we’ve developed QIAseq #NGS technologies, so you can simplify your day-to-day lab life, from faster workflows and reproducible results to straightforward NGS data analysis. Discover the power of QIAseq and skip several steps to success. Learn more. ⬇️

Have you been meaning to find out more about #VisiumHD? This blog is for you, introducing you to the basics of the HD technology and workflow, why the CytAssist matters, FAQs about sample compatibility and data analysis, and biological examples of the discovery power of high-resolution #spatialtranscriptomics. Check it out!

Check out the latest 10x blog on a whole new way to explore your FFPE tissue sections!

Bionano Introduces Stratys System for High Throughput Optical Genome Mapping (OGM) #bionanogenomics #stratyssystem #medtech #genomemapping #device #diagnosis #genome #technology #launch #commercial #company #hematological #saphyrinstrument

👨🔬 In this case study, JADBio was compared against Hyper-Parameter Optimization #ML libraries. Results show that in typical omics dataset analysis, JADBio manages to identify signatures comprising just a handful of features while maintaining competitive #predictive performance and accurate out-of-sample performance estimation. Read more here: https://bit.ly/3Dhxioe #knowledgediscovery #featureselection #autoML

How does Visium CytAssist make #spatialtranscriptomics sample management easier? What samples can you access with CytAssist? What additional spatial capabilities will be enabled on the instrument going forward? How have researchers already benefited from using it? ... We answer these questions in our latest blog, introducing the power of Visium CytAssist!

Sharing Endpoint webinar on CRISPR genome editing solutions from discovery to clinic - from RUO to cGMP. Not all cas9 will bind to gRNA giving rise to detection of free cas9 and variants. Best practices and methods in the manufacturing of cell and gene products are under way, to ensure greater standardisation and consistent characteristics of each lot of the RNP. The slides are informative and well covered. Don't miss the Q&A session, as there are more information to be revealed. https://lnkd.in/gg-z4WZt